Revenue reached RMB 4.53 billion, marking a 3.9% year-over-year increase, while R&D expenditure rose by 24.9% to RMB 680 million. The company currently holds RMB 19.4 billion in financial resources, providing a stable runway for its clinical pipeline. A major contributor to the period’s performance was the recognition of RMB 850 million in business development revenue, largely tied to the global licensing deal for SSGJ-707.
3SBio Interim Results Highlight Pivot to Global Innovation
3SBio reported a robust first half of 2026, with adjusted operating net profit climbing 26.5% to RMB 1.44 billion. The company accelerated its international footprint, fueled by a 43% surge in overseas sales and the rapid global clinical progression of its flagship anti-PD-1/VEGF bispecific antibody, SSGJ-707.
Commercial momentum remains anchored in the successful marketing approval of three Class 1 innovative drugs: Yisaituo for psoriasis, NuPIAO for chronic kidney disease, and Yisaina for gout. Looking ahead, 3SBio is preparing to scale its portfolio further, with five additional products currently under New Drug Application review. These candidates target high-growth therapeutic areas, including atopic dermatitis and oncology, as the company seeks to leverage its diversified pipeline to sustain long-term competitive advantages. Beyond clinical milestones, the firm’s commitment to sustainable operations was reflected in a recent upgrade to an 'AA' Wind ESG rating, placing it within the top 3.2% of the global biotechnology sector.
Comments (0)
No comments yet. Be the first!